Abstract
Peripheral T-cell lymphomas (PTCL) are a common type of non-Hodgkin lymphoma in China, with a higher incidence compared to Western countries. Apart from extranodal NK/T-cell lymphoma, nodal PTCL is the most prevalent subtype in China. Nodal PTCL is highly aggressive with a poor prognosis. Significant differences in molecular characteristics and clinical manifestations are observed among various subtypes, and the efficacy of conventional chemotherapy is limited. In recent years, the application of targeted therapies has significantly improved outcomes for some patients and is changing treatment paradigms for initial, maintenance, and relapsed disease. Based on these advancements, the Lymphoma Expert Committee of Chinese Society of Clinical Oncology and Lymphoid Disease Group, Chinese Society of Hematology, Chinese Medical Association have organized a panel of experts to develop this consensus, aiming to promote standardized diagnosis and treatment of nodal PTCL among clinicians in China, as well as to facilitate clinical research and application of novel therapies.